Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Neonatal Perinatal Med ; 14(2): 293-297, 2021.
Article in English | MEDLINE | ID: mdl-32804104

ABSTRACT

Central diabetes insipidus (CDI) may occur in the setting of intracranial abnormalities that affect the hypothalamus-pituitary system. It occurs rarely in neonates, especially in the premature population, and represents a challenging disease process to treat pharmacologically. Little is known regarding the treatment options in premature infants, including dose and route of administration of intravenous desmopressin (DDAVP). We present a case of a late premature male infant with gastroschisis and septo-optic dysplasia who developed transient CDI. He was treated with intravenous DDAVP but required frequent laboratory monitoring and a multidisciplinary approach, and ultimately his CDI resolved. Although there are minimal guidelines regarding the appropriate formulation and dosage of DDAVP for management of CDI in infants, we initiated the lowest dose available and titrated the medication based on close monitoring of urine output and serum sodium levels in order to successfully treat his transient CDI.


Subject(s)
Deamino Arginine Vasopressin/therapeutic use , Diabetes Insipidus, Neurogenic/drug therapy , Infant, Premature , Septo-Optic Dysplasia/drug therapy , Diabetes Insipidus, Neurogenic/complications , Diabetes Insipidus, Neurogenic/diagnosis , Humans , Infant, Premature, Diseases/drug therapy , Male , Septo-Optic Dysplasia/complications , Septo-Optic Dysplasia/diagnosis
3.
J Glaucoma ; 25(7): e713-7, 2016 07.
Article in English | MEDLINE | ID: mdl-27136085

ABSTRACT

INTRODUCTION: Previous studies have described septooptic dysplasia (SOD) to describe patients who have optic nerve hypoplasia, the absence of septum pellucidum, and pituitary hypoplasia. Other rare ophthalmic associations have been described, such as low-tension glaucoma. We report the ocular findings of a patient with SOD who had high intraocular pressure (IOP) and glaucoma as a part of the syndrome. OBJECTIVES: To report the ocular findings in a Puerto Rican patient with SOD and increased IOP. PATIENTS AND METHODS: A patient with De Morsier syndrome underwent a comprehensive eye examination, Humphrey visual fields, and Stratus optical coherence tomography, and was referred for neuroradiologic examination. The patient had increased IOP, visual field loss, and asymmetric optic nerve hypoplasia. The IOP was lowered with topical hypotensive medications. CONCLUSIONS: The patient with the De Morsier syndrome had poor visual acuity, high IOP, visual field, and optical coherence tomography results that were all compatible with glaucoma. Further studies comparing ocular findings in patients with several mutations leading to De Morsier syndrome are warranted. To our knowledge, this is the first report on a patient with glaucoma as a part of the syndrome.


Subject(s)
Intraocular Pressure/physiology , Low Tension Glaucoma/physiopathology , Septo-Optic Dysplasia/physiopathology , Aged , Antihypertensive Agents/therapeutic use , Female , Humans , Low Tension Glaucoma/diagnosis , Low Tension Glaucoma/drug therapy , Septo-Optic Dysplasia/diagnosis , Septo-Optic Dysplasia/drug therapy , Tomography, Optical Coherence , Vision Disorders/diagnosis , Vision Disorders/drug therapy , Vision Disorders/physiopathology , Visual Acuity/physiology , Visual Field Tests , Visual Fields/drug effects , Visual Fields/physiology
4.
J Clin Res Pediatr Endocrinol ; 6(2): 116-8, 2014.
Article in English | MEDLINE | ID: mdl-24932606

ABSTRACT

Septo-optic dysplasia (SOD) is a heterogeneous disorder of the central nervous system characterized by various endocrinological and neurological findings. It is a complex disease caused by a combination of genetic and environmental factors. Herein, we report the case of a 5.5-year-old girl who presented with short stature and strabismus. Ophthalmological examination revealed bilateral optic nerve hypoplasia. Ectopic posterior pituitary and bilateral optic hypoplasia were detected on brain magnetic resonance imaging. The presence of bilateral optic nerve hypoplasia and hypopituitarism led to the diagnosis of SOD. An abated growth hormone (GH) response was found in the GH stimulation test and GH replacement therapy was initiated. At the end of the first year of clinical follow-up, secondary hypothyroidism was detected and L-thyroxine was added to the treatment. At the age of 8.25 years, thelarche was noted and 6 months later, the patient presented with menarche. At this time, the bone age was 12 years and the basal luteinizing hormone level was 7 mIU/mL. These findings indicated acceleration in the process of pubertal development. We report this case (i) to emphasize the need to investigate hypopituitarism in cases with bilateral optic nerve hypoplasia and (ii) to draw attention to the fact that during the follow-up of SOD cases receiving GH therapy, inappropriate acceleration of growth velocity and rapid improvement in bone age may be predictive of central precocious puberty development.


Subject(s)
Human Growth Hormone/therapeutic use , Hypothyroidism/chemically induced , Puberty, Precocious/chemically induced , Septo-Optic Dysplasia/drug therapy , Child , Female , Humans , Recombinant Proteins/therapeutic use , Septo-Optic Dysplasia/complications , Sexual Maturation , Thyroxine
5.
Pituitary ; 13(2): 186-8, 2010 Jun.
Article in English | MEDLINE | ID: mdl-18814036

ABSTRACT

BACKGROUND: The anti-natriuretic properties of growth hormone (GH) are well established. Growth hormone deficiency (GHD) results in salt and water depletion and studies confirm that replacement leads to sodium and vasopressin-mediated water retention in patients with intact posterior pituitary function. METHODS: We report the case of a 20-year-old male patient with septo-optic dysplasia, fixed cranial diabetes insipidus (DI) and an abnormal thirst threshold. With careful parental support, his sodium levels remained stable for many years on a fixed dose of DDAVP and a supervised fluid intake of 2.5 l/day. Several years after the original diagnosis, he was found to be ACTH deficient and following commencement of hydrocortisone replacement therapy became hypernatraemic. A new sodium homoeostasis was established with a higher dose of DDAVP. Subsequently, he developed symptoms typical of GHD and, after biochemical confirmation, GH replacement was commenced. RESULTS: There was an immediate clinical improvement (increased alertness, improved concentration) but severe hypernatraemia developed (peak 169 mmol/l) necessitating revision of his desmopressin and fluid intake regimen. CONCLUSION: Most GHD patients have intact posterior pituitary function. This case report highlights the powerful anti-natriuretic properties of GH. Endocrine physicians should be alert to this in patients with fixed DI and an abnormal thirst threshold.


Subject(s)
Growth Hormone/adverse effects , Hormone Replacement Therapy/adverse effects , Hypernatremia/chemically induced , Septo-Optic Dysplasia/drug therapy , Growth Hormone/therapeutic use , Humans , Male , Young Adult
6.
Cogn Behav Neurol ; 21(4): 254-7, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19057177

ABSTRACT

BACKGROUND: Septo-optic dysplasia, a variable combination of abnormalities of cerebral midline structures, is a clinically heterogeneous syndrome in which the midline defects may be implicated in psychiatric disturbances. OBJECTIVE: To describe a case of septo-optic dysplasia associated with depression and psychosis and to discuss the role of these developmental abnormalities in psychiatric disturbances. METHODS: The patient's clinico-anamnestic, neuroradiologic, neuropsychiatric, endocrinologic, ophthalmologic, and genetic profile was evaluated. CONCLUSIONS: Developmental abnormalities due to disruption of the complex neural network linking the septum pellucidum with other limbic structures may have been involved in the affective and psychotic disturbances observed in our patient.


Subject(s)
Depressive Disorder/psychology , Psychotic Disorders/psychology , Septo-Optic Dysplasia/psychology , Antimanic Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Benzodiazepines/therapeutic use , Depressive Disorder/complications , Depressive Disorder/drug therapy , Female , Humans , Magnetic Resonance Imaging , Middle Aged , Neuropsychological Tests , Olanzapine , Psychotic Disorders/complications , Psychotic Disorders/drug therapy , Septo-Optic Dysplasia/complications , Septo-Optic Dysplasia/drug therapy , Tomography, X-Ray Computed , Valproic Acid/therapeutic use , Visual Fields , Wechsler Scales
SELECTION OF CITATIONS
SEARCH DETAIL
...